Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge
Gastroesophageal cancers have a poor prognosis despite the use of novel therapies, such as chemotherapy combinations and biologic agents. Recently, immune checkpoint inhibitors (ICIs) have also been introduced into the treatment landscape. The programmed cell death protein 1 (PD-1) inhibitor, pembro...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2019-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2019.02.008 |